These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 26463822)
41. Prophylactic acyclovir effectively reduces herpes simplex virus type 1 reactivation after exposure of latently infected mice to ultraviolet B. Blatt AN; Laycock KA; Brady RH; Traynor P; Krogstad DJ; Pepose JS Invest Ophthalmol Vis Sci; 1993 Nov; 34(12):3459-65. PubMed ID: 8225880 [TBL] [Abstract][Full Text] [Related]
42. Reactivation of acyclovir-resistant thymidine kinase-deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene. Morfin F; Thouvenot D; Aymard M; Souillet G J Med Virol; 2000 Oct; 62(2):247-50. PubMed ID: 11002255 [TBL] [Abstract][Full Text] [Related]
43. D-(+)-iso-methanocarbathymidine: a high-affinity substrate for herpes simplex virus 1 thymidine kinase. Comin MJ; Vu BC; Boyer PL; Liao C; Hughes SH; Marquez VE ChemMedChem; 2008 Jul; 3(7):1129-34. PubMed ID: 18399509 [TBL] [Abstract][Full Text] [Related]
44. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. Fyfe JA; Keller PM; Furman PA; Miller RL; Elion GB J Biol Chem; 1978 Dec; 253(24):8721-7. PubMed ID: 214430 [No Abstract] [Full Text] [Related]
45. N2-phenyldeoxyguanosine: a novel selective inhibitor of herpes simplex thymidine kinase. Focher F; Hildebrand C; Freese S; Ciarrocchi G; Noonan T; Sangalli S; Brown N; Spadari S; Wright G J Med Chem; 1988 Aug; 31(8):1496-500. PubMed ID: 2840499 [TBL] [Abstract][Full Text] [Related]
47. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus. Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626 [TBL] [Abstract][Full Text] [Related]
48. [Battle with herpes for 37 years]. Shimomura Y Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):145-66; discussion 167. PubMed ID: 25854108 [TBL] [Abstract][Full Text] [Related]
49. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Kokoris MS; Black ME Protein Sci; 2002 Sep; 11(9):2267-72. PubMed ID: 12192082 [TBL] [Abstract][Full Text] [Related]
50. Gamma interferon can block herpes simplex virus type 1 reactivation from latency, even in the presence of late gene expression. Decman V; Kinchington PR; Harvey SA; Hendricks RL J Virol; 2005 Aug; 79(16):10339-47. PubMed ID: 16051826 [TBL] [Abstract][Full Text] [Related]
51. Thymidine kinase not required for antiviral activity of acyclovir against mouse cytomegalovirus. Burns WH; Wingard JR; Bender WJ; Saral R J Virol; 1981 Sep; 39(3):889-93. PubMed ID: 6270357 [TBL] [Abstract][Full Text] [Related]
52. Suppression of herpes simplex virus type 1 reactivation from latency by (+-)-9-([(Z)-2-(hydroxymethyl)cyclohexyl]methyl) guanine (L-653,180) in vitro. Nsiah YA; Tolman RL; Karkas JD; Rapp F Antimicrob Agents Chemother; 1990 Aug; 34(8):1551-5. PubMed ID: 2171423 [TBL] [Abstract][Full Text] [Related]
53. Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes. Bourne N; Bravo FJ; Ashton WT; Meurer LC; Tolman RL; Karkas JD; Stanberry LR Antimicrob Agents Chemother; 1992 Sep; 36(9):2020-4. PubMed ID: 1329638 [TBL] [Abstract][Full Text] [Related]
54. Effects of mutations on herpes simplex virus 1 thymidine kinase functionality: an in vitro assay based on detection of monophosphate forms of acyclovir and thymidine using HPLC/DAD. Malartre N; Boulieu R; Falah N; Cortay JC; Lina B; Morfin F; Frobert E Antiviral Res; 2012 Sep; 95(3):224-8. PubMed ID: 22796575 [TBL] [Abstract][Full Text] [Related]
55. QSAR of N2-phenylguanidines as inhibitors of herpes simplex virus-1 thymidine kinase. Hadjipavlou-Litina D Pharmazie; 1995 Dec; 50(12):796-8. PubMed ID: 8584555 [TBL] [Abstract][Full Text] [Related]
56. A tracer kinetic model for 18F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET. Green LA; Nguyen K; Berenji B; Iyer M; Bauer E; Barrio JR; Namavari M; Satyamurthy N; Gambhir SS J Nucl Med; 2004 Sep; 45(9):1560-70. PubMed ID: 15347725 [TBL] [Abstract][Full Text] [Related]
57. Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus. Saijo M; Suzutani T; Itoh K; Hirano Y; Murono K; Nagamine M; Mizuta K; Niikura M; Morikawa S J Med Virol; 1999 Aug; 58(4):387-93. PubMed ID: 10421406 [TBL] [Abstract][Full Text] [Related]
58. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Black ME; Kokoris MS; Sabo P Cancer Res; 2001 Apr; 61(7):3022-6. PubMed ID: 11306482 [TBL] [Abstract][Full Text] [Related]
59. Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study. Frobert E; Ooka T; Cortay JC; Lina B; Thouvenot D; Morfin F Antiviral Res; 2007 Feb; 73(2):147-50. PubMed ID: 16970995 [TBL] [Abstract][Full Text] [Related]